<p>| <strong>Questions</strong>                                                                                                                                                                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| At what dose and route of administration should methotrexate be started?                                                                                                        |
| Does switching to non-methotrexate DMARDs improve tolerability over increasing the dose of folic acid, or using folinic acid or using split dose or subcutaneous dosing, for RA patients with side effects when taking methotrexate? |
| What is the efficacy of TTT in different patient populations (early versus late, bDMARD-or tsDMARD-exposed, elderly-onset, comorbidities)?                                      |